References
- Boyle KL, Leech E. A review of the pharmacology and clinical uses of pimobendan. J Vet Emerg Crit Care (San Antonio). 2012;22:398–408.
- Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart. 1996;76:223–231.
- University of Otago. Toxinz; 2019. Available from: https://www.toxinz.com
- Wylie CE, Cairns R, Brown JA, et al. Human exposures to veterinary pharmaceutical products reported to Australia’s largest Poison Information Centre. Clin Toxicol. 2019;1. doi:10.1080/15563650.2019.1572180
- Chu KM, Shieh SM, Hu OYP. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. Clin Pharmacol Ther. 1995;57:610–621.
- Kuriya Si, Ohmori S, Hino M, et al. Identification of cytochrome P-450 isoform (s) responsible for the metabolism of pimobendan in human liver microsomes. Drug Metabol Dispos. 2000;28:73–78.
- Hagemeijer F. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Eur Heart J. 1993;14:551–566.